Findings

What do systematic reviews say?

64 questions · 64 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 14.1%GRADE not reported 2 · 3.1%Very low 11 · 17.2%Low 17 · 26.6%Moderate 21 · 32.8%High 4 · 6.3%

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1080 participants
Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1080 participants
Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1080 participants
Very low